Peptide SMIM30 promotes HCC development by inducing SRC/YES1 membrane anchoring and MAPK pathway activation
- PMID: 32461121
- DOI: 10.1016/j.jhep.2020.05.028
Peptide SMIM30 promotes HCC development by inducing SRC/YES1 membrane anchoring and MAPK pathway activation
Abstract
Background & aims: Growing evidence shows that some non-coding RNAs (ncRNAs) contain small open reading frames (smORFs) that are translated into short peptides. Herein, we aimed to determine where and how these short peptides might promote hepatocellular carcinoma (HCC) development.
Methods: We performed an RNA-immunoprecipitation followed by high-throughput sequencing (RIP-seq) assay with an antibody against ribosomal protein S6 (RPS6) on 4 cancer cell lines. Focusing on 1 long non-coding RNA (lncRNA), LINC00998, we used qPCR and public databases to evaluate its expression level in patients with HCC. Special vectors were constructed to confirm its coding potential. We also explored the function and mechanism of LINC00998-encoded peptide in tumor growth and metastasis.
Results: We discovered that many lncRNAs bind to RPS6 in cancer cells. One of these lncRNAs, LINC00998, encoded a small endogenous peptide, termed SMIM30. SMIM30, rather than the RNA itself, promoted HCC tumorigenesis by modulating cell proliferation and migration, and its level was correlated with poor survival in patients with HCC. Furthermore, SMIM30 was transcribed by c-Myc and then drove the membrane anchoring of the non-receptor tyrosine kinases SRC/YES1. Moreover, the downstream MAPK signaling pathway was activated by SRC/YES1.
Conclusions: Our results not only unravel a new mechanism of HCC tumorigenesis promoted by ncRNA-encoded peptides, but also suggest that these peptides can serve as a new target for HCC cancer therapy and a new biomarker for HCC diagnosis and prognosis.
Lay summary: Very little is known about how peptides activate signaling pathways that play a crucial role in diseases such as cancer. Specifically, we reported on a conserved peptide encoded by LINC00998, SMIM30. This peptide promoted the tumorigenesis of hepatocellular carcinoma (HCC) by modulating cell proliferation and migration. Of note, it bound the non-receptor tyrosine kinases, SRC/YES1, to drive their membrane anchoring and phosphorylation, activating the downstream MAPK signaling pathway. Our work not only unravels a new mechanism of HCC tumorigenesis promoted by peptides, but also demonstrates how the peptide works to activate a signaling pathway.
Keywords: HCC; LINC00998; Peptide; SMIM30; ncRNAs.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
SMIM30, a tiny protein with a big role in liver cancer.J Hepatol. 2020 Nov;73(5):1010-1012. doi: 10.1016/j.jhep.2020.07.015. Epub 2020 Aug 22. J Hepatol. 2020. PMID: 32843211 No abstract available.
Similar articles
-
LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway.Biomed Pharmacother. 2018 Nov;107:824-833. doi: 10.1016/j.biopha.2018.08.079. Epub 2018 Aug 22. Biomed Pharmacother. 2018. PMID: 30142544
-
LINC00998-encoded micropeptide SMIM30 promotes the G1/S transition of cell cycle by regulating cytosolic calcium level.Mol Oncol. 2023 May;17(5):901-916. doi: 10.1002/1878-0261.13358. Epub 2022 Dec 29. Mol Oncol. 2023. PMID: 36495128 Free PMC article.
-
Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.Int J Med Sci. 2020 May 18;17(9):1224-1234. doi: 10.7150/ijms.45256. eCollection 2020. Int J Med Sci. 2020. PMID: 32547318 Free PMC article.
-
YES1: A Novel Therapeutic Target and Biomarker in Cancer.Mol Cancer Ther. 2022 Sep 6;21(9):1371-1380. doi: 10.1158/1535-7163.MCT-21-0958. Mol Cancer Ther. 2022. PMID: 35732509 Review.
-
Role of lncRNAs in hepatocellular carcinoma.Life Sci. 2023 Jul 15;325:121751. doi: 10.1016/j.lfs.2023.121751. Epub 2023 May 9. Life Sci. 2023. PMID: 37169145 Review.
Cited by
-
LncRNA-encoded peptides in cancer.J Hematol Oncol. 2024 Aug 12;17(1):66. doi: 10.1186/s13045-024-01591-0. J Hematol Oncol. 2024. PMID: 39135098 Free PMC article. Review.
-
Downregulation of SMIM3 inhibits growth of leukemia via PI3K-AKT signaling pathway and correlates with prognosis of adult acute myeloid leukemia with normal karyotype.J Transl Med. 2022 Dec 22;20(1):612. doi: 10.1186/s12967-022-03831-8. J Transl Med. 2022. PMID: 36550462 Free PMC article.
-
Functional Peptides Encoded by Long Non-Coding RNAs in Gastrointestinal Cancer.Front Oncol. 2021 Nov 23;11:777374. doi: 10.3389/fonc.2021.777374. eCollection 2021. Front Oncol. 2021. PMID: 34888249 Free PMC article. Review.
-
A microprotein N1DARP encoded by LINC00261 promotes Notch1 intracellular domain (N1ICD) degradation via disrupting USP10-N1ICD interaction to inhibit chemoresistance in Notch1-hyperactivated pancreatic cancer.Cell Discov. 2023 Sep 15;9(1):95. doi: 10.1038/s41421-023-00592-6. Cell Discov. 2023. PMID: 37714834 Free PMC article.
-
Biochemical targets of the micropeptides encoded by lncRNAs.Noncoding RNA Res. 2024 Apr 25;9(3):964-969. doi: 10.1016/j.ncrna.2024.04.005. eCollection 2024 Sep. Noncoding RNA Res. 2024. PMID: 38764490 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous